Biomarkers have moved from a research tool to a core part of how modern medicine is practiced. They help clinicians detect disease earlier, match patients to the right therapy, and help drug developers decide which candidates deserve further investment. According to Grand View Research, the global biomarkers market was valued at USD 81.0 billion in 2023. It is estimated at USD 117.1 billion in 2026 and projected to reach USD 194.2 billion by 2030, a CAGR of 13.4% from 2024 to 2030.

Dominant Growth Trends in 2026

1. Cancer remains the anchor of demand

Cancer was the leading disease segment in 2023 and is expected to hold that position through 2030. Rising global incidence is increasing the need for rapid, accurate diagnostic tools. Research into novel cancer biomarkers, including miRNA-based detection approaches and early-detection markers for aggressive cancers, is widening the market's scope. Public funding supports this: in early 2023, the U.S. National Institutes of Health committed USD 4 million to biomarker research for early detection of aggressive prostate cancer.

2. Precision medicine and companion diagnostics

The shift toward personalized treatment is a primary growth engine. Biomarkers identify who is likely to respond to a therapy, and who is at risk of adverse reactions. That pushes demand for the consumables used in biomarker discovery and validation, which led the product segment in 2023. Pharma-backed testing programs, such as those for ovarian and lung cancer, show how biomarker testing is being used to widen patient access to targeted drugs.

3. Blood-based biomarkers in neurology

Neurological disease is one of the most active frontiers. Biomarker signatures are enabling noninvasive testing, faster drug development, and earlier diagnosis. Recent milestones include Roche receiving FDA Breakthrough Device Designation for a blood-based amyloid panel for early Alzheimer's detection, and Labcorp launching a tri-biomarker blood test for Alzheimer's diagnosis in 2023.

4. Digital biomarkers enter clinical trials

Digital biomarkers give pharmaceutical sponsors continuous, contextual data to support clinical trial decisions. Partnerships such as Koneksa's work with SSI Strategy, and IXICO's collaborations with biopharma on validating digital biomarkers for regulated trials, show the category maturing from concept to practice.

5. Efficacy biomarkers and diagnostics are the fastest-growing segments

Safety biomarkers held the largest type share in 2023 at 37.62%, because they help predict adverse drug events and lower attrition in drug development. Efficacy biomarkers are expected to grow fastest through 2030. On the application side, drug discovery and development led in 2023, while diagnostics is projected to grow fastest.

6. Services and collaboration models

Biomarker services support trial design, patient stratification, and treatment-response monitoring. That makes the services segment one to watch. The market is also marked by partnerships among industry, academia, and consortia, which speed up both discovery and commercialization. Reimbursement frameworks remain a key variable, since they directly affect how quickly new diagnostic and prognostic tools reach patients.

The full Grand View Research report provides segment-level forecasts by type, product, application, disease, and region, along with detailed company profiles and competitive analysis. Download Free Sample Report to preview the market data, trend analysis, and forecasts.

Prominent Market Leaders

The competitive landscape combines diagnostics majors, life-science tools providers, and specialist testing companies. Companies profiled by Grand View Research include:

• F. Hoffmann-La Roche AG, a leader in blood-based neurological biomarkers
• Abbott
• Thermo Fisher Scientific Inc.
• QIAGEN
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• General Electric
• Eurofins Scientific
• Epigenomics AG

Leading players are investing in advanced technology and high-throughput infrastructure, pursuing geographic expansion, seeking regulatory approvals for new products, and forming partnerships and distribution agreements. Emerging participants such as Atlas Genetics, Hologic, Myriad Genetics, and Genomic Health focus on novel product launches and on funding from government bodies and healthcare organizations.

Recent launches show where the competition is heading. Mindray introduced high-sensitivity cardiac biomarkers (NT-proBNP and hs-cTnI), Quest Diagnostics partnered with Envision Sciences on a prostate cancer biomarker test, and Cardio Diagnostics launched an epigenetic-genetic blood test for coronary heart disease.

Go Deeper into the Biomarkers Market Speak to Analyst to discuss how these findings apply to your strategy.

Regional Dynamics

North America: the established leader

North America accounted for 43.9% of global revenue in 2023. The region benefits from a high disease burden, advanced technology, strong awareness, supportive government initiatives, and mature healthcare infrastructure. The local presence of major players, and close collaboration between them and universities and research centers, helps novel biomarkers reach the market faster. Investment in digital biomarkers adds further momentum.

Asia Pacific: the fastest-growing region

Asia Pacific is expected to post the fastest CAGR from 2024 to 2030. Drivers include a high prevalence of cancer, rising funding for discovery, lower clinical trial costs in developing economies, and expanding research initiatives. Growing R&D by biopharmaceutical companies in the region, including work on genetic markers for hard-to-treat cancers, is expected to support this growth.

Europe, Latin America, and Middle East & Africa

Grand View Research also covers Europe (including the UK, Germany, France, Italy, Spain, and the Nordics), Latin America (Brazil, Mexico, Argentina), and the Middle East & Africa (Saudi Arabia, UAE, South Africa, Kuwait), spanning 20+ countries in total.

What This Means for Stakeholders

• Diagnostics and tools companies: Consumables and software for biomarker discovery and validation are in sustained demand, and neurology and cardiology are rich areas for new tests.
• Pharma and biotech: Biomarker-guided development can reduce drug attrition and cost, and services partners can extend internal capabilities.
• Investors: The 13.4% CAGR, Asia Pacific's momentum, and active partnership activity point to opportunities across the value chain.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today